Cargando…
Ophthalmic manifestations in IgG4-related disease: Clinical presentation and response to treatment in a French case-series
IgG4-related disease (IgG4-RD) is characterized by variable tissue or organ involvements sharing common pathological findings. Orbital or orbital adnexa involvement of the disease has been reported in a few case series. The aim of our study was to characterize and analyze ophthalmic manifestations f...
Autores principales: | , , , , , , , , , , , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Wolters Kluwer Health
2017
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5348160/ https://www.ncbi.nlm.nih.gov/pubmed/28272212 http://dx.doi.org/10.1097/MD.0000000000006205 |
_version_ | 1782514182744178688 |
---|---|
author | Ebbo, Mikael Patient, Matthieu Grados, Aurelie Groh, Matthieu Desblaches, Julien Hachulla, Eric Saadoun, David Audia, Sylvain Rigolet, Aude Terrier, Benjamin Perlat, Antoinette Guillaud, Constance Renou, Frederic Bernit, Emmanuelle Costedoat-Chalumeau, Nathalie Harlé, Jean-Robert Schleinitz, Nicolas |
author_facet | Ebbo, Mikael Patient, Matthieu Grados, Aurelie Groh, Matthieu Desblaches, Julien Hachulla, Eric Saadoun, David Audia, Sylvain Rigolet, Aude Terrier, Benjamin Perlat, Antoinette Guillaud, Constance Renou, Frederic Bernit, Emmanuelle Costedoat-Chalumeau, Nathalie Harlé, Jean-Robert Schleinitz, Nicolas |
author_sort | Ebbo, Mikael |
collection | PubMed |
description | IgG4-related disease (IgG4-RD) is characterized by variable tissue or organ involvements sharing common pathological findings. Orbital or orbital adnexa involvement of the disease has been reported in a few case series. The aim of our study was to characterize and analyze ophthalmic manifestations from a nationwide French case-series. Patients with IgG4-RD and orbital or orbital adnexa involvement included in the French multicentric IgG4-RD case-registry were identified. Only patients fulfilling “modified” comprehensive diagnostic criteria with pathological documentation were retained for the study. Clinical, biological, pathological, radiological findings and data regarding the response to treatment were retrospectively analyzed. According to our data registry, the frequency of IgG4-related ophthalmic disease (IgG4-ROD) was 17%. Mean age at diagnosis was 55.1 ± 7.1 years with a male/female ratio of 2.2. The 19 cases of IgG4-ROD consisted of lacrimal gland (68.4%), soft tissue (57.9%), extra-ocular muscles (36.8%), palpebral (21.1%), optical nerve (10.5%), orbital bone (10.5%), and mononeuritis (V1 and/or V2, 10.5%) involvements. IgG4-ROD was bilateral in 57.9% of cases. Extra-ophthalmic manifestations were reported in 78.9% of cases. All patients responded to prednisone but two-thirds of patients relapsed within a mean (SD) of 9.8 (3.5) months and 72.2% required long-term glucocorticoids and/or immunosuppressive agents. Eight patients were treated by rituximab with a favorable response in 87.5% of cases. Lacrimal involvement is the most frequent ophthalmic manifestation of IgG4-RD and is frequently associated with extra-orbital manifestations. Despite initial favorable response to steroids, the long-term management of relapsing patients needs to be improved. |
format | Online Article Text |
id | pubmed-5348160 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2017 |
publisher | Wolters Kluwer Health |
record_format | MEDLINE/PubMed |
spelling | pubmed-53481602017-03-22 Ophthalmic manifestations in IgG4-related disease: Clinical presentation and response to treatment in a French case-series Ebbo, Mikael Patient, Matthieu Grados, Aurelie Groh, Matthieu Desblaches, Julien Hachulla, Eric Saadoun, David Audia, Sylvain Rigolet, Aude Terrier, Benjamin Perlat, Antoinette Guillaud, Constance Renou, Frederic Bernit, Emmanuelle Costedoat-Chalumeau, Nathalie Harlé, Jean-Robert Schleinitz, Nicolas Medicine (Baltimore) 3600 IgG4-related disease (IgG4-RD) is characterized by variable tissue or organ involvements sharing common pathological findings. Orbital or orbital adnexa involvement of the disease has been reported in a few case series. The aim of our study was to characterize and analyze ophthalmic manifestations from a nationwide French case-series. Patients with IgG4-RD and orbital or orbital adnexa involvement included in the French multicentric IgG4-RD case-registry were identified. Only patients fulfilling “modified” comprehensive diagnostic criteria with pathological documentation were retained for the study. Clinical, biological, pathological, radiological findings and data regarding the response to treatment were retrospectively analyzed. According to our data registry, the frequency of IgG4-related ophthalmic disease (IgG4-ROD) was 17%. Mean age at diagnosis was 55.1 ± 7.1 years with a male/female ratio of 2.2. The 19 cases of IgG4-ROD consisted of lacrimal gland (68.4%), soft tissue (57.9%), extra-ocular muscles (36.8%), palpebral (21.1%), optical nerve (10.5%), orbital bone (10.5%), and mononeuritis (V1 and/or V2, 10.5%) involvements. IgG4-ROD was bilateral in 57.9% of cases. Extra-ophthalmic manifestations were reported in 78.9% of cases. All patients responded to prednisone but two-thirds of patients relapsed within a mean (SD) of 9.8 (3.5) months and 72.2% required long-term glucocorticoids and/or immunosuppressive agents. Eight patients were treated by rituximab with a favorable response in 87.5% of cases. Lacrimal involvement is the most frequent ophthalmic manifestation of IgG4-RD and is frequently associated with extra-orbital manifestations. Despite initial favorable response to steroids, the long-term management of relapsing patients needs to be improved. Wolters Kluwer Health 2017-03-10 /pmc/articles/PMC5348160/ /pubmed/28272212 http://dx.doi.org/10.1097/MD.0000000000006205 Text en Copyright © 2017 the Author(s). Published by Wolters Kluwer Health, Inc. http://creativecommons.org/licenses/by-nc-sa/4.0 This is an open access article distributed under the terms of the Creative Commons Attribution-NonCommercial-ShareAlike 4.0 License, which allows others to remix, tweak, and build upon the work non-commercially, as long as the author is credited and the new creations are licensed under the identical terms. http://creativecommons.org/licenses/by-nc-sa/4.0 |
spellingShingle | 3600 Ebbo, Mikael Patient, Matthieu Grados, Aurelie Groh, Matthieu Desblaches, Julien Hachulla, Eric Saadoun, David Audia, Sylvain Rigolet, Aude Terrier, Benjamin Perlat, Antoinette Guillaud, Constance Renou, Frederic Bernit, Emmanuelle Costedoat-Chalumeau, Nathalie Harlé, Jean-Robert Schleinitz, Nicolas Ophthalmic manifestations in IgG4-related disease: Clinical presentation and response to treatment in a French case-series |
title | Ophthalmic manifestations in IgG4-related disease: Clinical presentation and response to treatment in a French case-series |
title_full | Ophthalmic manifestations in IgG4-related disease: Clinical presentation and response to treatment in a French case-series |
title_fullStr | Ophthalmic manifestations in IgG4-related disease: Clinical presentation and response to treatment in a French case-series |
title_full_unstemmed | Ophthalmic manifestations in IgG4-related disease: Clinical presentation and response to treatment in a French case-series |
title_short | Ophthalmic manifestations in IgG4-related disease: Clinical presentation and response to treatment in a French case-series |
title_sort | ophthalmic manifestations in igg4-related disease: clinical presentation and response to treatment in a french case-series |
topic | 3600 |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5348160/ https://www.ncbi.nlm.nih.gov/pubmed/28272212 http://dx.doi.org/10.1097/MD.0000000000006205 |
work_keys_str_mv | AT ebbomikael ophthalmicmanifestationsinigg4relateddiseaseclinicalpresentationandresponsetotreatmentinafrenchcaseseries AT patientmatthieu ophthalmicmanifestationsinigg4relateddiseaseclinicalpresentationandresponsetotreatmentinafrenchcaseseries AT gradosaurelie ophthalmicmanifestationsinigg4relateddiseaseclinicalpresentationandresponsetotreatmentinafrenchcaseseries AT grohmatthieu ophthalmicmanifestationsinigg4relateddiseaseclinicalpresentationandresponsetotreatmentinafrenchcaseseries AT desblachesjulien ophthalmicmanifestationsinigg4relateddiseaseclinicalpresentationandresponsetotreatmentinafrenchcaseseries AT hachullaeric ophthalmicmanifestationsinigg4relateddiseaseclinicalpresentationandresponsetotreatmentinafrenchcaseseries AT saadoundavid ophthalmicmanifestationsinigg4relateddiseaseclinicalpresentationandresponsetotreatmentinafrenchcaseseries AT audiasylvain ophthalmicmanifestationsinigg4relateddiseaseclinicalpresentationandresponsetotreatmentinafrenchcaseseries AT rigoletaude ophthalmicmanifestationsinigg4relateddiseaseclinicalpresentationandresponsetotreatmentinafrenchcaseseries AT terrierbenjamin ophthalmicmanifestationsinigg4relateddiseaseclinicalpresentationandresponsetotreatmentinafrenchcaseseries AT perlatantoinette ophthalmicmanifestationsinigg4relateddiseaseclinicalpresentationandresponsetotreatmentinafrenchcaseseries AT guillaudconstance ophthalmicmanifestationsinigg4relateddiseaseclinicalpresentationandresponsetotreatmentinafrenchcaseseries AT renoufrederic ophthalmicmanifestationsinigg4relateddiseaseclinicalpresentationandresponsetotreatmentinafrenchcaseseries AT bernitemmanuelle ophthalmicmanifestationsinigg4relateddiseaseclinicalpresentationandresponsetotreatmentinafrenchcaseseries AT costedoatchalumeaunathalie ophthalmicmanifestationsinigg4relateddiseaseclinicalpresentationandresponsetotreatmentinafrenchcaseseries AT harlejeanrobert ophthalmicmanifestationsinigg4relateddiseaseclinicalpresentationandresponsetotreatmentinafrenchcaseseries AT schleinitznicolas ophthalmicmanifestationsinigg4relateddiseaseclinicalpresentationandresponsetotreatmentinafrenchcaseseries |